Literature DB >> 12691734

The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar.

Philippe P Monnier1, Ana Sierra, Jan M Schwab, Sigrid Henke-Fahle, Bernhard K Mueller.   

Abstract

Axons fail to regenerate in the central nervous system after injury. Chondroitin sulfate proteoglycans (CSPG) expressed in the scar significantly contribute to the nonpermissive properties of the central nervous system environment. To examine the inhibitory activity of a CSPG mixture on retina ganglion cell (RGC) axon growth, we employed both a stripe assay and a nerve fiber outgrowth assay. We show that the inhibition exerted by CSPGs in vitro can be blocked by application of either C3 transferase, a specific inhibitor of the Rho GTPase, or Y27632, a specific inhibitor of the Rho kinase. These results demonstrate that CSPG-associated inhibition of neurite outgrowth is mediated by the Rho/ROCK signaling pathway. Consistent with these results, we found that retina ganglion cell axon growth on glial scar tissue was enhanced in the presence of C3 transferase and Y27632, respectively. In addition, we show that the recently identified inhibitory CSPG Te38 is upregulated in the lesioned spinal cord.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12691734     DOI: 10.1016/s1044-7431(02)00035-0

Source DB:  PubMed          Journal:  Mol Cell Neurosci        ISSN: 1044-7431            Impact factor:   4.314


  124 in total

1.  Crocetin Potentiates Neurite Growth in Hippocampal Neurons and Facilitates Functional Recovery in Rats with Spinal Cord Injury.

Authors:  Xiqian Wang; Xiejia Jiao; Zhonghao Liu; Yixin Li
Journal:  Neurosci Bull       Date:  2017-08-02       Impact factor: 5.203

2.  Autoantobodies activate small GTPase RhoA to modulate neurite outgrowth.

Authors:  Kazim A Sheikh
Journal:  Small GTPases       Date:  2011-07-01

3.  The developmental loss of the ability of Purkinje cells to regenerate their axons occurs in the absence of myelin: an in vitro model to prevent myelination.

Authors:  Lamia Bouslama-Oueghlani; Rosine Wehrlé; Constantino Sotelo; Isabelle Dusart
Journal:  J Neurosci       Date:  2003-09-10       Impact factor: 6.167

Review 4.  Proteoglycans as cues for axonal guidance in formation of retinotectal or retinocollicular projections.

Authors:  Hiroyuki Ichijo
Journal:  Mol Neurobiol       Date:  2004-08       Impact factor: 5.590

5.  Switching mature retinal ganglion cells to a robust growth state in vivo: gene expression and synergy with RhoA inactivation.

Authors:  Dietmar Fischer; Victoria Petkova; Solon Thanos; Larry I Benowitz
Journal:  J Neurosci       Date:  2004-10-06       Impact factor: 6.167

Review 6.  Reactive astrogliosis after spinal cord injury-beneficial and detrimental effects.

Authors:  Soheila Karimi-Abdolrezaee; Rohini Billakanti
Journal:  Mol Neurobiol       Date:  2012-06-09       Impact factor: 5.590

Review 7.  Lectican proteoglycans, their cleaving metalloproteinases, and plasticity in the central nervous system extracellular microenvironment.

Authors:  M D Howell; P E Gottschall
Journal:  Neuroscience       Date:  2012-05-22       Impact factor: 3.590

8.  Alterations in chondroitin sulfate proteoglycan expression occur both at and far from the site of spinal contusion injury.

Authors:  Ellen M Andrews; Rebekah J Richards; Feng Q Yin; Mariano S Viapiano; Lyn B Jakeman
Journal:  Exp Neurol       Date:  2011-09-17       Impact factor: 5.330

Review 9.  Molecular and Cellular Mechanisms of Axonal Regeneration After Spinal Cord Injury.

Authors:  Erna A van Niekerk; Mark H Tuszynski; Paul Lu; Jennifer N Dulin
Journal:  Mol Cell Proteomics       Date:  2015-12-22       Impact factor: 5.911

10.  Y-27632, a Rho-associated protein kinase inhibitor, attenuates neuronal cell death after transient retinal ischemia.

Authors:  Akira Hirata; Masaru Inatani; Yasuya Inomata; Naoko Yonemura; Takahiro Kawaji; Megumi Honjo; Hidenobu Tanihara
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2007-08-31       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.